Transmucosal fentanyl: the advantages of nasal delivery

HCP - Home - Block

Indications and Usage

Lazanda® (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

  • Patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer.
  • Patients must remain on around-the-clock opioids when taking Lazanda.
  • Lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

Limitations of Use

  • As a part of the TIRF REMS Access program, Lazanda may be dispensed only to outpatients enrolled in the program. [see Warnings and Precautions] For inpatient administration of Lazanda (e.g., hospitals, hospices, and long-term care facilities that prescribe for inpatient use), patient enrollment is not required.
Lazanda nasal spray

The first and only nasal transmucosal fentanyl

The pharmacokinetic profile of Lazanda is consistent with the dynamics of breakthrough cancer pain (BTPc).2,3

We also provide extensive support to simplify the prescription process and help ensure that your patients have access to Lazanda.

  • Pay no more than $5 for your prescription.
  • Find out how nasal delivery with Lazanda helps put you in control of your breakthrough cancer pain.